Kimberly Gonzales
Acute Care · Hattiesburg, MSNPI 1275824088
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 45.3% of the total. Reporting peaked in 2024 at $6,283 and has fallen 70.1% since, to $1,877 in 2025. Among acute care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $54.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
- Medtronic$2K
- Atricure, Inc.$1K
- Novartis$751
- E.r. Squibb & Sons, L.L.C.$541
- Boehringer Ingelheim$272
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$3,75036%
- Travel & lodging$1,92118%
- Food & beverage$4,64445%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 47 | $4,717 |
| Medtronic | 23 | $1,679 |
| Atricure, Inc. | 14 | $1,248 |
| Novartis | 12 | $751 |
| E.r. Squibb & Sons, L.L.C. | 32 | $541 |
| Boehringer Ingelheim | 8 | $272 |
| AstraZeneca | 8 | $205 |
| Johnson & Johnson | 11 | $196 |
| Gilead | 3 | $138 |
| Boston Scientific | 6 | $116 |
| AbbVie | 6 | $106 |
| Pfizer | 5 | $106 |
| Merck | 2 | $55 |
| Lexicon Pharmaceuticals, Inc. | 2 | $48 |
| Abiomed | 1 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Abbott | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| Biotronik Inc. | 1 | $19 |
| Novo Nordisk | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$3,750
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$872
- LEQVIO$224
- CAMZYOS$116
How this compares
$10,413 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $293,865 |
| XareltoRivaroxaban | 99 | $98,243 |
| EntrestoSacubitril/Valsartan | 86 | $74,880 |
| Dofetilide | 295 | $50,610 |
| JardianceEmpagliflozin | 40 | $39,787 |
| FarxigaDapagliflozin Propanediol | 34 | $35,061 |
| MyrbetriqMirabegron | 11 | $4,750 |
| Amiodarone Hcl | 302 | $4,587 |
| Metoprolol Succinate | 336 | $4,158 |
| Flecainide Acetate | 92 | $3,326 |
| SotalolSotalol Hcl | 134 | $1,969 |
| Potassium Chloride | 93 | $1,742 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $1,317 |
| Losartan Potassium | 119 | $752 |
| Nebivolol Hcl | 14 | $720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $293,865341 claims |
| Johnson & JohnsonXarelto | $196 | $98,24399 claims |
| NovartisEntresto | $751 | $74,88086 claims |
| Boehringer IngelheimJardiance | $272 | $39,78740 claims |
| AstraZenecaFarxiga | $205 | $35,06134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.
Other acute care in Hattiesburg
- Dylan BoydHattiesburg$15K
- Billy ChancellorHattiesburg$9K
- Brad MasseyHattiesburg$4K
- Ronald TynesHattiesburg$3K
- Garrett BondHattiesburg$2K
- Christopher BellTupelo$348K
- Kathleen ArnoldOcean Springs$217K
- Gavin GistOxford$42K
- Jamie DamicoOcean Springs$17K
- Melinda ClarkStarkville$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.